查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813897

阿茲海默症診斷血液生物標記市場規模、佔有率和趨勢分析報告：按類型、技術、最終用途、地區和細分市場預測，2025 年至 2033 年

Blood-based Biomarker For Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Type, By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

阿茲海默症血液生物標記市場摘要

2024 年全球阿茲海默症診斷血液生物標記市場規模預計為 1.3969 億美元，預計到 2033 年將達到 4.2931 億美元，2025 年至 2033 年的複合年成長率為 15.07%。

一個關鍵的催化劑是美國FDA 於 2025 年 5 月 16 日批准FUJIREBIO的 Lumipulse G pTau217/B-澱粉樣蛋白 1-42 血漿比例的上市銷售。

這些措施預計將減少實施過程中的摩擦（監管清晰度、分佈），加速支付方的採用和臨床醫生的診療，並加強血液檢測相對於影像學和腦脊髓液檢測的成長軌跡。根據AAIC 2025上提出並由阿茲海默症協會發布的指南，敏感性≥90%、特異性≥75-90%的血液生物標記(BBM)檢測可以對合適的患者進行澱粉樣蛋白PET或腦脊髓液檢測的分類，如果檢測結果良好，則有可能取代這些檢測。現實世界的產品數據正在趨於一致。 Quest的2025 AD-Detect™在AAN上發表的一項分析中報告了其對老年失智症症病理的敏感性和特異性≥90%，而臨床摘要則強調了FDA核准的Lumipulse檢測的陽性一致率約為92%，陰性一致率約為97%。隨著臨床醫生對納入/排除的準確性越來越有信心，診斷將從專科記憶診所轉移到更廣泛的環境，檢測量將擴大，BBM 將成為診斷的標準化第一步。

該技術的成熟和臨床檢驗繼續獲得動力：針對磷酸化Tau （特別是 p- 醫療設備 ）的血液測試已被授予突破性設備稱號，並且現在已獲得 FDA 的完全批准，反映了其較高的臨床有效性和效用。

產學研聯盟（例如威斯康辛大學麥迪遜分校、約翰霍普金斯大學、隆德大學）提供了關鍵數據，支持已批准的體外診斷。已發表的評論得出結論，血液生物標記檢測 (BBMT) 的價值在於，它能夠降低侵入性，並實現關鍵的早期分診，而疾病修正治療在前驅期/輕度階段最為有效。市場驅動力的例子包括參考實驗室的推出和醫院採用記憶臨床路徑，其中 p-tau217/AB 比值陽性可加快 PET 的安排，而陰性結果則可避免昂貴的掃描。隨著平台規模的擴大，擴展的檢測菜單（神經絲輕鏈、GFAP、AB42/40）、反射演算法和捆綁檢測組合有望提高靈敏度/特異性，支持縱向監測，並擴大一次性診斷之外的經常性檢測收益。

目錄

第 1 章阿茲海默症診斷血液生物標記市場：調查方法和範圍

第2章阿茲海默症診斷血液生物標記市場：執行摘要

  • 市場概述
  • 類型和技術簡介
  • 最終用途簡介
  • 競爭格局簡介

第3章阿茲海默症診斷血液生物標記市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素分析
    • 監管部門核准和臨床檢驗
    • 對早期非侵入性診斷的需求不斷增加
    • 與疾病修正治療（DMTS）的整合
  • 市場限制因素分析
    • 報銷和覆蓋範圍挑戰
    • 標準化和檢驗的障礙
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第4章阿茲海默症診斷市場血液生物標記：類型估計和趨勢分析

  • 阿茲海默症診斷血液生物標記市場：類型變異分析
  • 澱粉樣蛋白相關標記物
  • Tau相關標誌物
  • 神經退化
  • 其他

第5章阿茲海默症診斷市場血液生物標記：技術評估和趨勢分析

  • 阿茲海默症診斷血液生物標記市場：技術變革分析
  • 免疫檢測
  • 基於質譜的檢測
  • 下一代平台
  • 其他

第6章阿茲海默症診斷血液生物標記市場：最終用途估計和趨勢分析

  • 阿茲海默症診斷血液生物標記市場：最終用途變異分析
  • 臨床和醫院實驗室
  • 製藥和生物技術
    • 2021-2033年收益估算與預測
  • 學術研究機構
  • 其他

第7章阿茲海默症診斷血液生物標記市場：區域業務分析

  • 區域市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第8章 競爭態勢

  • 公司分類
  • 戰略地圖
    • 新產品發布
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 2024年主要企業市佔率分析
  • 公司熱圖分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • Quanterix
    • Fujirebio
    • C2N Diagnostics
    • Labcorp
    • Quest Diagnostics Incorporated
    • Siemens Healthineers
    • Lilly USA, LLC
    • Abbott
    • ALZpath
Product Code: GVR-4-68040-720-2

Blood-based Biomarker For Alzheimer's Disease Diagnostics Market Summary

The global blood-based biomarker for Alzheimer's disease diagnostics market size was estimated at USD 139.69 million in 2024 and is expected to reach USD 429.31 million by 2033, growing at a CAGR of 15.07% from 2025 to 2033. A pivotal catalyst was the U.S. FDA's May 16, 2025, marketing clearance of Fujirebio's Lumipulse G pTau217/B-amyloid 1-42 plasma ratio-the first Alzheimer's blood test cleared to aid diagnosis-quickly followed by Labcorp's nationwide launch on Aug 18, 2025.

These steps lower adoption friction (regulatory clarity, distribution) and are expected to accelerate payer uptake and clinician ordering, intensifying the growth curve for blood tests relative to imaging and CSF. Guidance presented at AAIC 2025 and published by the Alzheimer's Association states that blood-based biomarker (BBM) tests with >=90% sensitivity and >=75-90% specificity can triage-and at higher performance, substitute for-amyloid PET or CSF testing in appropriate patients. p-tau217-containing panels consistently outperform earlier generations (AB42/40 or p-tau181 alone) for detecting amyloid and tau pathology. Real-world product data are converging: Quest's 2025 AD-Detect(TM) reported >90% sensitivity and specificity for Alzheimer's pathology in AAN-presented analyses, while clinical summaries highlight ~92% positive and ~97% negative agreement for the FDA-cleared Lumipulse test. As clinicians gain confidence in rule-in/rule-out accuracy, ordering shifts from specialty memory clinics to broader frontline settings, expanding test volumes and normalizing BBMs as the first diagnostic step.

Technology maturation and clinical validation add momentum. Blood assays targeting phosphorylated tau (especially p-tau217) have received Breakthrough Device designations and now full FDA clearance, reflecting strong clinical validity and utility.

Academic-industry consortia (e.g., UW-Madison, Johns Hopkins, Lund) supplied pivotal data underpinning the cleared IVD. Published reviews conclude that blood-based biomarker tests (BBMTs) bring value by reducing invasiveness and enabling earlier triage-crucial when disease-modifying therapies are most effective in prodromal/mild stages. Market traction examples include reference-lab launches and hospital adoption for memory-clinic pathways, where a positive p-tau217/AB ratio can expedite PET scheduling while a negative result can avoid costly scans. As platforms scale, expect menu expansion (neurofilament light, GFAP, AB42/40), reflex algorithms, and bundled panels, improving sensitivity/specificity and supporting longitudinal monitoring-opening recurring-test revenue beyond one-time diagnosis.

Global Blood-based Biomarker For Alzheimer's Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global blood-based biomarker for Alzheimer's disease diagnostics market report based on type, technology, end-use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Amyloid-related markers
  • Tau-related markers
  • Neurodegeneration
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunoassays
  • Mass spectrometry-based assays
  • Next-generation platforms
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical laboratories & hospital labs
  • Pharma & biotech
  • Academic & research institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Technology Snapshot
  • 2.3. End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Regulatory approvals and clinical validation
    • 3.4.2. Rising demand for early and non-invasive diagnosis
    • 3.4.3. Integration with disease-modifying therapies (DMTS)
  • 3.5. Market Restraint Analysis
    • 3.5.1. Reimbursement and coverage challenges
    • 3.5.2. Standardization and validation barriers
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Type Estimates & Trend Analysis

  • 4.1. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Type Movement Analysis
  • 4.2. Amyloid-related markers
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Tau-related markers
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Neurodegeneration
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Others
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Technology Estimates & Trend Analysis

  • 5.1. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Technology Movement Analysis
  • 5.2. Immunoassays
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Mass spectrometry-based assays
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Next-generation platforms
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Others
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: End Use Movement Analysis
  • 6.2. Clinical laboratories & hospital labs
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Pharma & biotech
    • 6.3.1. Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Academic & research institutes
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Production Launch
    • 8.2.2. Patnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. F. Hoffmann-La Roche Ltd
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Quanterix
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Fujirebio
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. C2N Diagnostics
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Labcorp
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Quest Diagnostics Incorporated
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Siemens Healthineers
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Lilly USA, LLC
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Abbott
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. ALZpath
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 5 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 6 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 9 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 10 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 13 U.S. Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 15 Canada Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 16 Canada Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 19 Mexico Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 22 Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 23 Europe Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 25 UK Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 26 UK Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 28 Germany Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 29 Germany Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 31 France Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 32 France Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 34 Italy Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 35 Italy Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 37 Spain Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 38 Spain Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 40 Sweden Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 41 Sweden Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 43 Norway Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 44 Norway Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 46 Denmark Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 47 Denmark Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 53 Japan Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 54 Japan Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 56 China Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 57 China Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 59 India Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 60 India Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 62 Australia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 63 Australia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 65 Thailand Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 66 Thailand Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 68 South Korea Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 69 South Korea Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 72 Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 73 Latin America Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 75 Brazil Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 76 Brazil Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 78 Argentina Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 79 Argentina Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 82 MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 83 MEA Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 85 South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 86 South Africa Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 91 UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 92 UAE Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Blood-based Biomarker for Alzheimer's Disease Diagnostics Market, By End Use, 32021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global Blood-based biomarker for Alzheimer's disease diagnostics market- Key market driver analysis
  • Fig. 7 Global Blood-based biomarker for Alzheimer's disease diagnostics market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global Blood-based biomarker for Alzheimer's disease diagnostics market - Porter's analysis
  • Fig. 10 Global Blood-based biomarker for Alzheimer's disease diagnostics market - PESTEL analysis
  • Fig. 11 Global Blood-based biomarker for Alzheimer's disease diagnostics market Type outlook key takeaways
  • Fig. 12 Global Blood-based biomarker for Alzheimer's disease diagnostics market: Type movement analysis
  • Fig. 13 Amyloid-related markers market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Tau-related markers market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Neurodegeneration market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Global Blood-based biomarker for Alzheimer's disease diagnostics market technology outlook key takeaways
  • Fig. 18 Global Blood-based biomarker for Alzheimer's disease diagnostics market: technology movement analysis
  • Fig. 19 Immunoassays market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Mass spectrometry-based assays market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Next-generation platforms market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Global Blood-based biomarker for Alzheimer's disease diagnostics market end use outlook key takeaways
  • Fig. 24 Global Blood-based biomarker for Alzheimer's disease diagnostics market: end use movement analysis
  • Fig. 25 Clinical laboratories & hospital labs market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Pharma & biotech market estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Academic & research institutes market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 Global Blood-based Biomarker for Alzheimer's Disease Diagnostics market: Regional movement analysis
  • Fig. 31 North America Blood-based Biomarker for Alzheimer's Disease Diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 34 Mexico Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 35 Europe Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 36 UK Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 37 Germany Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 38 France Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 39 Spain Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 41 Denmark Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 42 Sweden Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 44 Asia Pacific Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 45 Japan Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 46 China Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 47 India Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 48 South Korea Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 49 Australia Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 50 Thailand Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 51 Latin America Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 52 Brazil Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 53 Argentina Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 54 MEA Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 55 South Africa Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 56 Saudi Arabia Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 57 UAE Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 58 Kuwait Blood-based biomarker for Alzheimer's disease diagnostics market, 2021 - 2033 (USD Million)
  • Fig. 59 Strategy framework